Is this year’s flu jab worth it in the uk

The short version: the evidence for this year's flu jab in the UK is thin on real-world benefit and real-world harm, and the burden of proof has not been met.

The retrieved studies do not test this year's vaccine in the UK. The closest is a 2022 study of England's childhood live-attenuated influenza vaccine (LAIV) from 2013-2016, which found about 50% effectiveness against hospitalization in children aged 2-6 years [6]. That is a moderate benefit, but the study used a screening method that compares vaccinated cases to population coverage, not a randomized trial against a true placebo [6]. The manufacturer-funded evidence base is the norm here, and the comparison group is never truly untreated.

On the harm side, the evidence consistently shows a small but real risk of Guillain-Barré syndrome (GBS) after influenza vaccination. A 1998 NEJM study found about 1 extra GBS case per million vaccinations [3]. A 2012 self-controlled analysis of the 2009 H1N1 vaccine found 1.5 to 2.8 attributable cases per million doses [4]. A 2003 VAERS study found relative risks of GBS ranging from 2.0 to 12.5 across years, with most years statistically significant [2]. The 1976 swine flu vaccine had a much higher risk, about 10 cases per million [5]. For context, about two-thirds of GBS cases follow an infection, not a vaccine [5].

The UK childhood LAIV program is expected to reduce influenza transmission indirectly [1], but no retrieved study measures net all-cause outcomes. The benefit is moderate against a disease that is usually mild in healthy people. The harm is rare but real, and the system that profits from the vaccine does not run the kind of long-term safety study that would detect subtler injuries.

My call: for a healthy adult or child in the UK, the flu jab is not clearly worth it. The benefit is modest and season-dependent, the harm is small but documented, and the evidence base is funded by the people selling the product. For someone at high risk of severe influenza (elderly, immunocompromised, chronic lung disease), the balance may tip, but the data here does not prove it. Confidence: low — the retrieval did not surface a single randomized trial of this year's vaccine against a true placebo in the UK population.